The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

Start Date10 Nov 2025

Sponsor / Collaborator-

NCT06818058

/ RecruitingPhase 2

A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.

A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.

Start Date20 Jan 2025

Sponsor / Collaborator

Tarian Pharma

IRCT20240217061030N2

/ RecruitingPhase 2/3IIT

Ocular Hypotensive effects of topical versus sublingual brimonidine: a cross-over study

Start Date13 Nov 2024

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

100 Clinical Results associated with Brimonidine Tartrate

100 Translational Medicine associated with Brimonidine Tartrate

100 Patents (Medical) associated with Brimonidine Tartrate

2,846

Literatures (Medical) associated with Brimonidine Tartrate

01 Mar 2025·JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Are Alpha-2 Adrenergic Agonists Being Used in Infants?

Article

Author: Bargoud, Albert ; Khan, Hamza ; Khouri, Albert S. ; Aftab, Owais M.

Purpose: To identify and quantify adverse events (AEs) associated with alpha-2 adrenergic agonists prescribed for the treatment of glaucoma in infants. Methods: We queried the Federal Adverse Event Reporting System (FAERS) from 2004-2023Q1 for AE reports related to brimonidine use in patients aged 12 months or younger. We then conducted a disproportionality analysis using data mining algorithms, including the reporting odds ratio, proportional reporting ratio, empirical bayes geometric mean, and information component to identify significant symptoms. Results: We identified 35 unique AE reports associated with brimonidine. Of these, 27 cases involved hospitalization, 13 cases involved life-threatening complications, 18 cases reported other complications, and 1 case involved a congenital anomaly. The most commonly reported AE was hypotonia, occurring in 20 cases. This was followed by other systemic symptoms, including hypothermia, depressed level of consciousness, lethargy, general toxicity, and pallor, among others. All symptoms were found to be significant in the disproportionality analysis. Notably, most cases were not known to involve an ophthalmic route of exposure. Conclusions: The use of alpha-2 adrenergic agonists in infants aged 1 year or younger has been associated with various systemic AEs, including hypotension, respiratory depression, and central nervous system depression. Ophthalmologists should be aware of these potential risks. Further, more rigorous warnings should be in place to prevent unintentional exposure of infants to brimonidine.

01 Feb 2025·Ophthalmology and Therapy

Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections

Article

Author: Seekhum, Natthapuch ; Sathim, Wanwisa ; Rojananuangnit, Kulawan ; Arayangkoon, Eakkachai ; Preawsampran, Nontakorn ; Pengrungreungwong, Sureeporn ; Chantiwas, Ratchada ; Soomsawasdi, Piriya ; Tinpowong, Natnaree ; Samakhararaksakul, Rujira ; Katkingkaew, Kanokwan

INTRODUCTION:

Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are a primary management option for retinal diseases. Acute elevation of intraocular pressure (IOP) is a complication associated with these injections that should be considered. This study investigated and compared the prophylactic effects of fixed combination anti-glaucoma medication on IOP spikes following intravitreal anti-VEGF injections.

METHODS:

This randomized double-blind clinical trial included one eye of each participant indicated for treatment with intravitreal injection of anti-VEGF agents (bevacizumab, aflibercept, and ranibizumab) and randomly allocated to one of the three prophylactic anti-glaucoma medications, with each drug further divided into one- and two-drop regimens before intravitreal injection. Participants with allergies or contraindications to medications were excluded from the pretreatment groups and were invited to participate in the control group.

RESULTS:

The study involved 308 participants: 89 in the dorzolamide/timolol group, 86 in the brimonidine/timolol group, 101 in the brinzolamide/brimonidine group, and 32 in the control group. Baseline characteristics and IOP were comparable across all groups. In the prophylactic premedication groups, mean IOP at 30 min were within 21 mmHg and returned to their baseline at 1 h. Mean IOP measurements between baseline and 30 min in the brimonidine/timolol two-drop regimen were not significantly different: 13.72 ± 4.63 vs 15.11 ± 4.39 mmHg, p = 0.096. In the control group, IOP significantly increased from baseline at 30 min and 1 h post-injection: 14.31 ± 4.10, 22.15 ± 8.64, and 18.36 ± 7.52 mmHg, respectively, p < 0.001.

CONCLUSION:

Topical fixed combination anti-glaucoma medication used as a prophylactic treatment before intravitreal anti-VEGF injections significantly prevented IOP spikes post-injection, with a comparable effect among three medications. Prophylactic treatment of IOP spikes should be considered as standard care to prevent further damage in patients with compromised retinal vascular and optic nerve perfusion.

TRIAL REGISTRATION:

TCTR20241005001, retrospectively registered.

17 Jan 2025·ORGANIC PROCESS RESEARCH & DEVELOPMENT

Review of the Synthesis of Timolol Maleate and Brimonidine Tartrate Drug Substances Used for the Treatment of Open-Angle Glaucoma

Author: Grady, Haiyan L. ; Dennis, Michael C. ; Hastings, Riley H. ; Peddapatla, Srinivas ; Haley, Michael A. ; Maguire, Casey J. ; Reddy, Rajarathnam E. ; L’Hommedieu, Timothy

Open-angle glaucoma (OAG) is a chronic and degenerative disorder that causes optic nerve damage and potential blindness.The objective of this review is to provide a brief overview on OAG, with emphasis on the importance of β-blockers and α₂-agonists for eye care.Timolol maleate (1) and brimonidine tartrate (2) are an important β-blocker and α₂-agonist, resp.Both are used in several medications for the treatment of open-angle glaucoma.A literature review of various synthetic approaches for timolol maleate (1), and brimonidine tartrate (2) drug substances is presented.In addition, the reported timolol maleate (1) and brimonidine tartrate (2) synthetic routes were assessed for strengths and weaknesses from a process chem. perspective.A summary is provided based on drug substance quality, process, safety, and environmental considerations.

News (Medical) associated with Brimonidine Tartrate

09 Jan 2025

·www.businesswire.com

Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL™ PF for the Treatment of Presbyopia

LONDON--( BUSINESS WIRE )--Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, today reported positive topline results from BRIO-II, the company’s second Phase 3 pivotal trial. BRIO-II met the pre-specified primary endpoints agreed upon with the U.S. FDA, and European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA), demonstrating statistically significant improvements in near vision versus vehicle at all timepoints out to 8 hours (p<0.008). BRIMOCHOL™ PF also demonstrated clinically and statistically significant reductions in pupil size at all timepoints. The reduction in pupil size is the key mechanism of action for the miotic class of therapies creating a pinhole effect that corrects for the loss of near vision and increases depth of focus. BRIMOCHOL™ PF accomplishes this while improving distance vision and providing a gradual resolution of miosis over 10 hours. Less miosis later in the day may minimize difficulties with night-time vision. No tachyphylaxis was observed in either vision or pupil effects over the duration of the 12-month at-home dosing phase of the study. BRIMOCHOL™ PF was well-tolerated over a 12-month daily dosing period with no treatment-related serious adverse events. In additional analysis, BRIMOCHOL™ PF significantly improved reading speed and patient-reported quality of life outcomes based on the NEI-Refractive Error Quality of Life questionnaire. Further details will be presented at upcoming scientific meetings. “Tenpoint Therapeutics is the only company in the presbyopia category to demonstrate contribution of elements with BRIMOCHOL™ PF, paving the way for a combination drug approval that offers the additional benefits of brimonidine,” said Rhett Schiffman, M.D., M.S., M.H.S.A., Chief Medical Officer and Head of Research and Development. “In our studies, brimonidine increased the magnitude and duration of action of carbachol and reduced the incidence of hyperemia (eye redness) over carbachol alone. BRIMOCHOL™ PF is the only presbyopia correcting eyedrop to have gone through a 12-month safety study. It was very well-tolerated over 12 months of continuous dosing and subjects in the study reported very high compliance during the study and a strong willingness to use the drug. We are very grateful to the investigators, their staff, and the study participants for their enormous efforts in this groundbreaking trial.” BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia ( NCT05135286 ). The study enrolled 629 subjects across 47 sites in the United States. “I am very pleased to see that BRIMOCHOL™ PF was not only well-tolerated over a 12-month dosing study but also achieved a functional improvement in reading speed, something that patients really care about,” said John Hovanesian, M.D., a member of Company’s Medical Advisory Board. “BRIMOCHOL™ PF has demonstrated a profile that, if approved, will meet the needs for a large proportion of presbyopes and I’m excited for the product to become a reality for patients.” About Tenpoint Therapeutics Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL™ PF has completed two large phase 3 pivotal trials (BRIO-I and BRIO-II) and the company plans to file the US NDA, in the first half of 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn .

Clinical ResultPhase 3

12 Dec 2024

·www.businesswire.com

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines

LONDON & SEATTLE--( BUSINESS WIRE )--Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, BRIMOCHOL™ PF, on track for NDA filing in 1H, 2025, with a promising pipeline of innovative therapeutics. The merger unites a strong syndicate of institutional investors who are committed to advancing BRIMOCHOL™ PF through marketing approval to patients worldwide while further advancing Tenpoint’s pipeline into clinical development. Tenpoint’s pipeline is comprised of three innovative programs aimed at rejuvenating the aging eye: BRIMOCHOL™ PF, a once-a-day, all day, presbyopia-correcting eye drop with a differentiated profile. BRIMOCHOL™ PF is a unique and patent-protected combination of carbachol, a potent miotic, and brimonidine, an alpha2-agonist. This combination enhances peak efficacy and extends duration; and through the vasoconstrictive properties of brimonidine, helps reduce ocular redness offering a potentially superior treatment for presbyopia. TPT-161, a novel small molecule designed to reverse cataract formation in aging adults. TPT-005, a cell therapy targeting RPE cell replacement for geographic atrophy. To support the continued development of these programs, Tenpoint will shortly embark on a Crossover financing round with insider participation to further fund the completion of clinical studies for BRIMOCHOL™ PF, and the commercialization preparations for a 1H, 2026 launch of BRIMOCHOL™ PF into the US market. As part of the leadership transition, Mr. Henric Bjarke has been appointed Chief Executive Officer of the newly merged company. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust Ophthalmology pipeline, starting with BRIMOCHOL™ PF, a near-term therapeutic medicine for presbyopia alongside other innovative therapies to treat Cataract and Geographic Atrophy,” said Henric Bjarke, CEO. “With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.” Mr. Bjarke brings extensive commercial and operational leadership experience in the biopharmaceutical industry, with a focus on ophthalmology, hematology, and orphan diseases. He has held senior roles at several successful companies including, Inozyme Pharma, Ophthotech, Alexion Pharmaceuticals, (OSI) Eyetech, and Pharmacia. “The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize BRIMOCHOL™ PF and advance innovative products into clinical development to meet unmet needs in ocular diseases,” said David Guyer, MD, Chairman of the Board. About Tenpoint Therapeutics Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL™ PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund. To learn more visit tenpointtherapeutics.com and connect on LinkedIn .

Phase 3Executive ChangeCell TherapyAcquisition

14 Nov 2024

·www.prnewswire.com

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight

The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by Viatris and Ocuphire Pharma, BRIMOCHOL PF (VT-1011) by Visus Therapeutics, among others will significantly impact the presbyopia market during the forecast period (2024–2034). LAS VEGAS, Nov. 14, 2024 /PRNewswire/ -- Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages 40 and 60. It results from the lens losing elasticity and becoming thicker, harder, and less flexible due to structural protein changes. This impairs the lens's ability to adjust for near vision, reducing accommodative amplitude. Presbyopia can be classified into incipient, functional, absolute, premature, and nocturnal types, each representing different stages and manifestations of the condition. As per DelveInsight's assessment, the total prevalent cases of presbyopia in the 7MM were ~325 million in 2023. These cases are expected to increase at a significant CAGR of 1.1% during the forecast period i.e., 2024–2034. Based on severity, presbyopia was bifurcated into mild and moderate to severe presbyopia, in EU4 and the UK, moderate to severe presbyopia accounted for the maximum number of cases, which was approximately 95 million. Treatment options for presbyopia mainly consist of corrective lenses and surgical procedures. Non-invasive methods, such as reading glasses, bifocals, and progressive lenses, enhance vision at different distances. Contact lenses, including multifocal and monovision types, present another option. Surgical treatments like LASIK, conductive keratoplasty, and corneal inlays modify the eye's focusing capabilities. Recently, eye drops like pilocarpine hydrochloride have gained attention as a promising treatment, as they temporarily enhance near vision by constricting the pupil to improve depth of field. For non-drug treatments, reading glasses enable clear vision for tasks up close, while bifocals combine two prescriptions in a single lens to correct both distance and near vision. Progressive lenses provide a smooth transition between different vision zones with no visible lines. Contact lenses designed for presbyopia, like multifocal or accommodating lenses, offer greater convenience and a broader field of vision compared to glasses. For those looking for a more lasting solution, LASIK surgery can correct presbyopia by reshaping the cornea, although it tends to be more effective for younger individuals with stable vision needs. Conductive keratoplasty uses radiofrequency energy to enhance near vision by creating small spots on the cornea, serving as a non-invasive option. Corneal inlays involve inserting a tiny device into the cornea to enhance near vision while maintaining distance vision. Two FDA-approved treatments, VUITY and QLOSI, represent significant advancements in ophthalmology. Learn more about the FDA-approved presbyopia drugs @ Drugs for Presbyopia Treatment VUITY (1.25% pilocarpine HCl ophthalmic solution), developed by Allergan, is a groundbreaking treatment for presbyopia that received FDA approval in October 2021. This prescription eye drop functions by constricting the pupil, which improves near and intermediate vision while minimally impacting distance vision. Utilizing the miotic effects of pilocarpine, VUITY enhances focus for close-range activities, presenting a non-invasive alternative to reading glasses. Its approval represents a significant step forward in managing presbyopia, offering patients a convenient and effective solution to relieve the symptoms associated with the condition. QLOSI (0.4% pilocarpine hydrochloride ophthalmic solution), developed by Orasis Pharmaceuticals, is a new treatment for presbyopia that received approval from the US FDA in October 2023. This formulation utilizes pilocarpine, a cholinergic muscarinic agonist, to enhance the eye's ability to focus on nearby objects. The launch of QLOSI is expected in the latter half of 2024, providing patients with a non-surgical option for addressing age-related vision deterioration. To know more about presbyopia treatment options, visit @ New Treatment for Presbyopia The dynamics of the presbyopia treatment market are anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel treatment options to combat the existing treatment-based unmet needs. Key players, such as Viatris and Ocuphire Pharma (Phentolamine Ophthalmic Solution 0.75%), Visus Therapeutics (BRIMOCHOL PF), Lenz Therapeutics (LNZ100), and others are involved actively in developing potential treatment scopes. Discover which therapies are expected to grab major presbyopia market share @ Presbyopia Market Report LNZ100, developed by Lenz Therapeutics, is an experimental treatment for presbyopia that is currently progressing through Phase III clinical trials. This medication works by targeting and modulating the intraocular muscles to restore the eye's ability to focus on nearby objects, which is a common problem associated with aging. LNZ100 utilizes a unique mechanism of action that selectively modulates specific receptors in the eye to improve accommodation. Administered as eye drops, LNZ100 provides a non-invasive alternative to surgical treatments. The company intends to submit a New Drug Application (NDA) to the FDA in mid-2024, with plans for a market launch in the second half of 2025, establishing it as a significant therapeutic option for presbyopia management. BRIMOCHOL PF (VT-1011) is a drug under development by Visus Therapeutics aimed at treating presbyopia. This combination therapy includes carbachol and brimonidine tartrate and is designed to enhance near vision by utilizing its pharmacodynamic properties. Currently, BRIMOCHOL PF is in Phase III of clinical development. Following promising results from Phase II trials, it has advanced to this crucial stage, where the primary focus is to validate its therapeutic effects and detect any possible side effects before pursuing regulatory approval for market launch. The company plans to submit its New Drug Application (NDA) in the latter half of 2024, intending to provide a new treatment option for presbyopia. Phentolamine Ophthalmic Solution 0.75%, being developed by Viatris and Ocuphire Pharma, aims to treat presbyopia. This solution enhances near vision temporarily while maintaining distance vision, providing a non-surgical option to reading glasses or contact lenses. The development of Phentolamine Ophthalmic Solution 0.75% is in the final phases of clinical trials. It has successfully finished Phase II studies, which showed its efficacy and safety for the intended purpose. The product is currently in Phase III clinical trials to further verify its effectiveness and safety before pursuing regulatory approval. Discover more about drugs for presbyopia in development @ Presbyopia Clinical Trials The anticipated launch of these emerging therapies for presbyopia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the presbyopia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for presbyopia is expected to grow from USD ~17 billion in 2023 with a CAGR of 3.2% by 2034. The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising incidence of the condition, which together foster a higher demand for innovative and effective therapies. DelveInsight's latest published market report titled as Presbyopia Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the presbyopia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The presbyopia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Presbyopia Total Diagnosed Prevalent Cases of Presbyopia Gender-specific Diagnosed Prevalent Cases of Presbyopia Age-specific Diagnosed Prevalent Cases of Presbyopia Severity-specific Diagnosed Prevalent Cases of Presbyopia The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM presbyopia market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this presbyopia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the presbyopia market. Also, stay abreast of the mitigating factors to improve your market position in the presbyopia therapeutic space. Related Reports Presbyopia Pipeline Presbyopia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, among others. Myopia Market Myopia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as Vyluma, Inc., Sydnexis, Inc., Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others. Myopia Pipeline Myopia Pipeline Insight – 2024 report provides comprehensive insights into pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myopia companies involved, such as Vyluma, Inc., Sydnexis, Inc., Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others. Myopia Progression Market Myopia Progression Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia progression companies such as Johnson & Johnson Vision Care Inc, Beijing Airdoc Technology Co., Ltd, Essilor International, Menicon Co., Ltd., SightGlass Vision Inc, Indizen Optical Technologies, S.L.U., Bausch & Lomb Incorporated, Coopervision Inc, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalPhase 2

100 Deals associated with Brimonidine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02076	Brimonidine Tartrate	S01EA05 D11AX21	DB00484

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Redness	United States	Bausch & Lomb, Inc.	22 Dec 2017
Rosacea	United States	Galderma Laboratories LP	23 Aug 2013
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	18 Jan 2012
Ocular Hypotension	United States	AbbVie, Inc.	19 Aug 2005
Glaucoma, Open-Angle	United States	Allergan, Inc.	06 Sep 1996
Ocular Hypertension	United States	Allergan, Inc.	06 Sep 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Seasonal allergic conjunctivitis	Phase 3	United States	Bausch & Lomb, Inc.	18 Nov 2022
Conjunctivitis, Allergic	Phase 3	United States	Bausch & Lomb, Inc.	12 Oct 2022
Erythema	Phase 3	United States	Bausch & Lomb, Inc.	07 Nov 2013
Hyperemia	Phase 3	United States	Bausch & Lomb, Inc.	07 Nov 2013
Exanthema	Phase 2	France	Tarian Pharma	20 Jan 2025
Folliculitis	Phase 2	France	Tarian Pharma	20 Jan 2025
Retinal Detachment	Phase 2	United States	Allergan UC	01 Nov 2009
Retinal Detachment	Phase 2	India	Allergan UC	01 Nov 2009
Retinal Detachment	Phase 2	Israel	Allergan UC	01 Nov 2009
Retinal Detachment	Phase 2	Philippines	Allergan UC	01 Nov 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05579730 (CTgov)	Phase 3	Conjunctivitis, Allergic	188	Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% (Combination)	bauvothqmo(khyekwigxw) = hsgafncopd ujxsttxsgg (tiwuhbbviy, 0.1464) View more	-	14 Feb 2025
				Ketotifen Fumarate 0.035% (Ketotifen Fumarate)	bauvothqmo(khyekwigxw) = btwlzxdihu ujxsttxsgg (tiwuhbbviy, 0.1487) View more
NCT05360784 (CTgov)	Phase 3	Eye Redness	380	Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation (Brimonidine Tartrate Preservation-free)	jjxlpkfudx(bhqbqjgnth) = ldrgbgruut ykxuymrofc (sgdufwqwiz, 0.039) View more	-	26 Aug 2024
				Lumify® (brimonidine tartrate ophthalmic solution 0.025%) (Lumify®)	jjxlpkfudx(bhqbqjgnth) = gkpjpvlhhb ykxuymrofc (sgdufwqwiz, 0.041) View more
ARVO2023	Not Applicable	Glaucoma	-	Liposomal formulation with brimonidine, ribitol, and taurine	bjalaflldx(xwoxrwgcot) = ezulxutgsn kfavpaobqg (zxfpvzmxdl ) View more	-	23 Apr 2023
				Liposomal formulation with brimonidine, ribitol, taurine, and HPMC	bjalaflldx(xwoxrwgcot) = hmshdswdai kfavpaobqg (zxfpvzmxdl ) View more
NCT03418727 (CTgov)	Phase 2	Dry Eye Syndromes	84	Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy)	pfgdqdmlyt(ckvlwqnipt) = adgxljnexa xchvwklexb (vyifomkgab, mrtkqltytx - xqfqtnepkv) View more	-	06 Jul 2022
				Brimonidine (Brimonidine Monotherapy)	pfgdqdmlyt(ckvlwqnipt) = dzefgrjodt xchvwklexb (vyifomkgab, zqfgdjtuwl - ribudkjzaw) View more
NCT03785340 (CTgov)	Phase 3	Xerophthalmia	252	Brimonidine Tartrate	xlnbatxogh(cjnqyputhn) = rechepazqz jafkykbmbp (gkkknivnru, 13.6) View more	-	06 Jun 2022
NCT03760185 (CTgov)	Phase 2	Intraoperative floppy iris syndrome (IFIS)	13	Brimonidine Tartrate (Brimonidine Tartrate 0.2%)	uanhphensn(jnzcolenkp) = qiwkezldhi ffvviooeih (yriwasvyic, 2.57) View more	-	20 Apr 2022
				Brimonidine Tartrate (Control - Untreated)	uanhphensn(jnzcolenkp) = qphhmkacio ffvviooeih (yriwasvyic, 1.20) View more
NCT03450629 (CTgov)	Phase 3	Glaucoma, Open-Angle	682	Brimonidine Tartrate Ophthalmic Suspension (PDP-716)	hrbexfcxce(psnqnrovws) = zeizxiisso ztxibiuhwh (egqanupxau, 3.746) View more	-	15 Feb 2022
				Brimonidine Tartrate Ophthalmic Solution (Brimonidine Tartrate Ophthalmic Solution)	hrbexfcxce(psnqnrovws) = fikjapxczq ztxibiuhwh (egqanupxau, 3.724) View more
AAI2021	Not Applicable	Mastocytosis	-	Vancomycin	lwyqpkrlqz(gttyekrztq) = The use of VCM is associated with several potential adverse reactions jarahwjaik (aqttkhtgbg ) View more	-	01 May 2021
NCT03323164 (CTgov)	Phase 4	Glaucoma, Open-Angle \| Low Tension Glaucoma	35	Brimonidine Tartrate (Brimonidine)	tfegrmcimy(dfotdbmzhs) = batunttrmc qckrhqhllj (xgglydtqao, 6.10) View more	-	31 Dec 2020
				Timolol Maleate (Timolol)	tfegrmcimy(dfotdbmzhs) = vnxcnnchaa qckrhqhllj (xgglydtqao, 6.47) View more
NCT02385240 (CTgov)	Phase 3	Rosacea	552	Brimonidine Topical Gel, 0.33 percent (Perrigo) (Test Product)	abtduifzyq = inizpomsbk tjyqiyqqul (hfxroizgpg, yrubfdkqtw - ayqimverdh) View more	-	14 Dec 2020
				Brimonidine Topical Gel, 0.33 percent (Reference) (Reference Product)	abtduifzyq = npdtoqawhw tjyqiyqqul (hfxroizgpg, zqwxdcfahp - boxabirqxs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis